Yahoo India Web Search

Sign In

Search results

      • Randomized trials report that single-inhaler triple therapy is more effective than dual bronchodilators at reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). However, this effect may have been influenced by the forced withdrawal of inhaled corticosteroids (ICS) at randomization.

      Single-Inhaler Triple versus Dual Bronchodilator Therapy in ...

  2. People also ask

  3. www.ncbi.nlm.nih.gov › pmc › articlesComparative efficacy of single-inhaler triple therapies for COPD:...

    Aug 5, 2021 · 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Reports recommends that patients with clinically significant symptoms and exacerbations of chronic obstructive pulmonary disease (COPD) should escalate to triple therapy, a combined use of inhaled corticosteroids (ICS), long-acting muscarinic antagonists (LAMA) and long-acting ...

    • Yixuan Jiang, Hao Hu, Siu-wai Leung, Siu-wai Leung
    • 10.1371/journal.pone.0255545
    • 2021
    • PLoS One. 2021; 16(8): e0255545.

  4. www.ncbi.nlm.nih.gov › pmc › articlesWhen to use single-inhaler triple therapy in COPD: a ...

    Feb 13, 2019 · The panel suggested three criteria, any one of which identifies a high-risk patient where escalation to triple therapy from monotherapy or double combination treatment is appropriate: 1) at least two exacerbations treated with oral corticosteroids, antibiotics, or both in the previous year; 2) at least one severe exacerbation that required hospi...

    • S Gaduzo, V McGovern, J Roberts, JE Scullion, D Singh
    • 10.2147/COPD.S173901
    • 2019
    • 2019

  5. Videos

    View all

  6. openres.ersjournals.com › content › 8/1/00333-2021Is single-inhaler triple therapy for COPD cost-effective in ...

    Conclusions FF/UMEC/VI single-inhaler triple therapy improved health outcomes and was a cost-effective option compared with FF/VI or UMEC/VI for patients with symptomatic COPD and a history of exacerbations in the UK at recognised cost-effectiveness threshold levels.

    • Is single-Inhaler triple therapy effective in patients with COPD?1
    • Is single-Inhaler triple therapy effective in patients with COPD?2
    • Is single-Inhaler triple therapy effective in patients with COPD?3
    • Is single-Inhaler triple therapy effective in patients with COPD?4
    • Is single-Inhaler triple therapy effective in patients with COPD?5

  7. www.ncbi.nlm.nih.gov › pmc › articlesTriple therapy in COPD: understanding the data - PMC

    Jan 30, 2023 · Effectiveness of single-inhaler triple therapy on exacerbation risk and mortality in COPD is exaggerated in IMPACT and ETHOS trials from confounding by prior ICS discontinuation: effectiveness fades in analyses and studies with no prior ICS discontinuation https://bit.ly/3tOgNdW.

    • Samy Suissa
    • ERJ Open Res. 2023 Jan; 9(1): 00615-2022.
    • 10.1183/23120541.00615-2022
    • 2023/01

  8. pubmed.ncbi.nlm.nih.gov › 39049587Extrafine single inhaler triple therapy effectiveness in COPD ...

    Background: The extrafine single inhaler triple therapy (efSITT) containing beclomethasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg has proved to be efficacious in patients with chronic obstructive pulmonary disease (COPD) in randomized control trials.

  9. journal.chestnet.org › article › S0012-3692(22)03715Single vs Multiple Inhaler Triple Therapy in the COPD ... - CHEST

    Jul 1, 2022 · The choice of either pursuing multiple-inhaler triple therapy (MITT) vs single-inhaler triple therapy (SITT) is based on a combination of prescribers’ preferences, patients’ preferences, costs, and medical consideration such as concomitant asthma.

  10. respiratory-research.biomedcentral.com › articlesSingle-inhaler triple therapy in patients with chronic ...

    Nov 4, 2019 · Guidelines recommend that treatment with a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), i.e. triple therapy, is reserved for a select group of symptomatic patients with chronic obstructive pulmonary disease (COPD) who continue to exacerbate despite treatment with dual therapy ...